Is AOD-9604 from Lumera Labs HPLC verified?

Yes. Every AOD-9604 lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is AOD-9604 sold for human use?

No. AOD-9604 is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is AOD-9604 shipped?

AOD-9604 is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for AOD-9604?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

Home / Catalog / Metabolic / AOD-9604 5 mg

4.7 · 176 researcher reviews

Growth axis · hGH fragment

AOD-9604

SKU LUM-AOD-5 · C₇₈H₁₂₃N₂₃O₂₃S₂ · 1815.05 g/mol · CAS 221231-10-3

A modified analog of the human growth-hormone hGH(177-191) C-terminal fragment, studied for lipolytic activity independent of full-length hGH receptor activation.

Purity (HPLC): ≥ 99.05%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$65CAD / 5 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

AOD-9604 is a 16-residue synthetic analog of the C-terminal fragment of human growth hormone (hGH 177-191) with an added N-terminal tyrosine. The peptide retains the lipolytic/anti-lipogenic activity of hGH without measurable activity at the hGH-receptor or IGF-1 induction, making it a useful research tool for isolating the lipolytic pathway.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

Lipolysis assays in 3T3-L1 adipocytes, comparative β-adrenergic vs. AOD-9604-mediated FFA release, in-vitro fat-oxidation profiling, and structural studies of the hGH C-terminal fragment.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge)
Molecular formula	C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular weight	1815.05 g/mol
CAS number	221231-10-3
Length	16 residues

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2628: 99.04%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2628

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.04% main peak
ESI-MS (positive)	1815.0 Da (theor. 1815.05)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Heffernan MA et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142(12):5182–5189.

Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9401) of human growth hormone. Horm Res. 2000;53(6):274–278.

Stier H et al. Safety and tolerability of AOD9604 in obese males. Trials. 2013;14:248.

Citing this material

AOD-9604 reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-AOD-5, Lot 26-A031.

Related · Growth axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

5 mg · ≥ 99.0%

$36 CADView →

AOD-9604

Overview

Research applications

Identity

Quality

Lot LM-2628

Verification

Reconstitution

Storage after reconstitution

Selected references

Citing this material

Often paired in studies.

Tirzepatide

Retatrutide

Cagrisema

AOD-9604

Why Lumera